Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2020 pubmed 9 citations

Antimicrobial Synergy of a Ribonuclease and a Peptide Secreted by Human Cells.

Eller. Chelcie H CH; Raines. Ronald T RT

Key Findings

  • LL‑37 alone has antimicrobial activity against Gram‑negative bacteria
  • RNase 1 alone is non‑toxic but becomes lethal to E. coli when combined with LL‑37
  • The combination works at picomolar concentrations and allows RNase 1 to enter bacterial cells

Practical Outcomes

  • For biohackers, the finding hints that pairing LL‑37 with RNase 1 could boost antibacterial effects, but the research is still in the lab stage. No safe dosage or delivery method for humans is provided, so it’s not ready for direct use yet.

Summary

The study shows that the human antimicrobial peptide LL‑37 can team up with the enzyme RNase 1 to kill E. coli bacteria much more effectively than either alone, even at extremely low (picomolar) doses.

Abstract

LL-37 is a secretory peptide that has antimicrobial activity. Ribonuclease 1 (RNase 1) is a secretory enzyme that is not cytotoxic. We find that human LL-37 and human RNase 1 can act synergistically to kill Gram-negative bacterial cells. In the presence of nontoxic concentrations of LL-37, RNase 1 is toxic to <i>Escherichia coli</i> cells at picomolar levels. Using wild-type RNase 1 and an inactive variant labeled with a fluorophore, we observe the adherence of RNase 1 to <i>E. coli</i> cells and its cellular entry in the presence of LL-37. These data suggest a natural means of modulating the human microbiome via the cooperation of an endogenous peptide (37 residues) and small enzyme (128 residues).

Study Information

Provider

pubmed

Year

2020

Date

2020-10-15T00:00:00.000Z

DOI

10.1021/acsinfecdis.0c00594

Citations

9

References

58